Answers are grounded in this paper and cite their sources.
Observational analysis finds novel biomarker profile predicts targeted therapy response in NSCLC, suggesting enhanced treatment strategies.
High IFN-γ expression, low Ki-67 and MA levels, and ≤ 2 elevated LCTM components constitute a favorable biomarker profile for predicting response to targeted therapy in advanced NSCLC. These biomarkers could aid in predicting early response and therapeutic stratification. The proposed "driver-clone-dependent clone" co-regulation mechanism underscores the clinical value of multi-biomarker evaluation. Further multi-center prospective studies are warranted for validation.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: